Medicare drug coverage

Tyvaso: 2027 Medicare Part D coverage

173 of 5,495 Part D plans (3%) list Tyvaso on their 2027 formulary, the plan's list of covered drugs (the same share as 2026). 35% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

2027 compared with 2026

Tyvaso is number 63 by total Medicare Part D spending in 2024 ($729 million). Plans that list it most often put it on tier 5 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 16 RxNorm products for this name.

Tyvaso Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it184 (3%)173 (3%)no change
Prior authorization (of plans that list it)69 (38%)54 (31%)-7 points
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)47 (26%)58 (34%)+8 points
Any of the three (of plans that list it)69 (38%)61 (35%)-3 points
Not listed or restricted (of all plans)5,403 (98%)5,383 (98%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

For pharmaciesFor agencies

Formulary tier

Tyvaso formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 13 (2%)0 (0%)
Tier 21 (1%)0 (0%)
Tier 40 (0%)7 (4%)
Tier 5180 (98%)166 (96%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 0 of them (0%) added prior authorization, step therapy, or a quantity limit for Tyvaso, and 16 stopped listing it.

Tyvaso: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 202716 (0%)
Listed it in 2027, not in 20262 (0%)
Moved it to a higher tier0 (0%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit0 (0%)
Added at least one of the three0 (0%)
Removed at least one of the three0 (0%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Tyvaso off the formulary or list it with prior authorization, step therapy, or a quantity limit. 41 states tie for the highest share, 100%; Maryland ranks last at 80%. States at the same share are ordered by the prior authorization or step therapy share; states equal on both shares share a rank, marked Tied.

States from most to least restrictive for Tyvaso, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Pennsylvania324100%8%no change
2New Mexico68100%4%no change
3New Jersey74100%3%no change
Tied 4Alaska9100%0%no change
Tied 4Alabama115100%0%no change
Tied 4Arkansas86100%0%no change
Tied 4Arizona148100%0%no change
Tied 4Connecticut54100%0%no change
Tied 4Delaware43100%0%no change
Tied 4Florida549100%0%no change
Tied 4Iowa64100%0%no change
Tied 4Idaho45100%0%no change
Tied 4Illinois133100%0%no change
Tied 4Indiana140100%0%no change
Tied 4Kansas84100%0%no change
Tied 4Kentucky123100%0%no change
Tied 4Louisiana126100%0%no change
Tied 4Massachusetts92100%0%no change
Tied 4Maine52100%0%no change
Tied 4Michigan183100%0%no change
Tied 4Minnesota63100%0%no change
Tied 4Missouri171100%0%no change
Tied 4Mississippi105100%0%no change
Tied 4Montana27100%0%no change
Tied 4North Carolina177100%0%no change
Tied 4North Dakota26100%0%no change
Tied 4Nebraska51100%0%no change
Tied 4New Hampshire25100%0%no change
Tied 4New York215100%0%no change
Tied 4Ohio173100%0%no change
Tied 4Oklahoma81100%0%no change
Tied 4Rhode Island29100%0%no change
Tied 4South Carolina91100%0%no change
Tied 4South Dakota30100%0%no change
Tied 4Tennessee157100%0%no change
Tied 4Texas412100%0%no change
Tied 4Utah53100%0%no change
Tied 4Vermont14100%0%no change
Tied 4Wisconsin97100%0%no change
Tied 4West Virginia70100%0%no change
Tied 4Wyoming13100%0%no change
42Nevada10097%0%-3 points
Tied 43Virginia14596%0%no change
Tied 43Oregon9296%0%no change
45Georgia15195%0%no change
46Colorado10690%0%+3 points
Tied 47Hawaii5088%0%no change
Tied 47California39788%0%no change
Tied 49Washington11486%0%+1 point
Tied 49District of Columbia2186%0%-2 points
51Maryland4980%0%-4 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Tyvaso off or restrict it.

Tyvaso coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
HealthPartners, Inc.70%none list it100%no change0
Johns Hopkins Healthcare LLC70%none list it100%no change0
Network Health, Inc.70%none list it100%no change0
Singh Holdings LLC7100%100%100%no change0
Astiva Health Holdings Incorporated80%none list it100%no change0
Healthfirst, Inc.80%none list it100%no change0
Longevity Health Founders, LLC80%none list it100%no change0
MVP Health Care, Inc.80%none list it100%no change0
Martin's Point Health Care, Inc.80%none list it100%no change0
Triton Health Systems, L.L.C.80%none list it100%no change0
DOCTORS HEALTHCARE PLANS, INC.90%none list it100%no change0
EmblemHealth, Inc.90%none list it100%no change0
Perennial Consortium, LLC90%none list it100%no change0
West Virginia United Health System, Inc.90%none list it100%no change0
Aware Integrated, Inc.100%none list it100%no change0
Gemstone Holdings, Inc.100%none list it100%no change0
Intermountain Health Care, Inc.100%none list it100%no change0
Thomas Jefferson University100%none list it100%no change0
ATRIO Health Plans110%none list it100%no change0
Curana Health Holdings, LLC120%none list it100%no change0
Fallon Community Health Plan, Inc.120%none list it100%no change0
Louisiana Health Service & Indemnity Company120%none list it100%no change0
Cambia Health Solutions, Inc.130%none list it100%no change0
Clover Health Holdings, Inc.130%none list it100%no change0
Henry Ford Health System130%none list it100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing